Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma (EFFORTS)
Vestibular Schwannoma
About this trial
This is an interventional treatment trial for Vestibular Schwannoma focused on measuring Facial nerve outcomes, Vestibular schwannoma resection, Acoustic neuroma, Omega-3, Nerve regeneration, Neuroprotection
Eligibility Criteria
Inclusion Criteria:
- VS on final pathology report
- Surgical intervention (RS, MF, TL, other)
- Primary and revision cases included, including prior radiation
Exclusion Criteria:
- History of liver disease or abnormal liver function tests
- Diabetic patients with specific contraindication to omega-3 supplementation
- History of bleeding disorder, or recommended use of anticoagulation (not including anti-platelets or NSAIDs) during the treatment period
- Neurofibromatosis 1 or 2, or schwanomatosis disorders
- Non-VS pathology
- Patients already taking fish oil/omega-3 supplementation.
Sites / Locations
- Mayo Clinic in Rochester
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Omega-3 Group
Placebo Group
Subjects will receive omega-3 supplementation (Nature's Bounty Fish Oil 1400 mg, containing 980 mg Omega-3 per capsule), to begin taking 3 days prior to surgical resection of their vestibular schwannoma. Subjects will continue to take the omega-3 supplementation for 6 weeks post-operatively.
Subjects will receive a placebo to begin taking 3 days prior to clinical care of surgical resection of vestibular schwannoma. Subjects will continue to take the placebo for 6 weeks post-operatively.